Latest Safety News

Page 8 of 252
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
NRW Holdings delivered record FY26 revenue and earnings after folding Fredon into a new EMIT division, while debt-funded expansion lifted leverage. The company enters FY27 with A$7.5 billion of secured work, a larger banking facility and a sharper test of whether diversification can keep converting into cash.
Victor Sage
Victor Sage
27 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Kelsian Group has entered FY27 after a record financial year, the $149.9 million sale of its Tourism Portfolio and a sharp reduction in leverage. But the transport operator is also awaiting an independent review into a fatal June bus incident as it pursues fresh international growth.
Victor Sage
Victor Sage
27 Oct 2026
West Wits Mining has nearly tripled monthly underground development at Qala Shallows and says the project remains funded through to steady-state production. Stoping is scheduled to begin in February 2027, while surface infrastructure has reached 61% completion.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
Locksley Resources is redirecting its exploration effort towards a district-scale copper-gold strategy in New South Wales, backed by A$13.383 million in cash. The company has also abandoned further investment in its Rice University antimony technology after concluding the commercial case was too uncertain.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Elevra Lithium delivered record mining volumes and US$74 million in North American Lithium revenue during the September quarter, while unit costs fell and cash increased to US$319 million. The company has now moved its NAL expansion into execution, but six recordable injuries and unsettled shipment pricing add important caveats to an otherwise strong operational update.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Valiant Gold has moved its Comet mine restart from re-entry into a construction and commissioning phase, with power, ventilation and dewatering systems advancing ahead of a H2 FY27 production target. The company ended the September quarter with $62.5 million in cash and term deposits while drilling at Reedy continued to test resource growth.
Maxwell Dee
Maxwell Dee
26 Oct 2026

Browse the archive

Full archive